Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Global, Regional and National Burden of Bladder Cancer, 1990 to 2016: Results From the Gbd Study 2016 Publisher Pubmed



Ebrahimi H1 ; Amini E2 ; Pishgar F1, 2 ; Moghaddam SS1, 3 ; Nabavizadeh B2 ; Rostamabadi Y1, 4 ; Aminorroaya A1, 4 ; Fitzmaurice C5 ; Farzadfar F1 ; Nowroozi MR2 ; Black PC6 ; Daneshmand S7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Stud. Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Institute for Health Metrics and Evaluation, Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, United States
  6. 6. Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
  7. 7. Norris Comprehensive Cancer Center, University of Southern California Institute of Urology, Los Angeles, CA, United States

Source: Journal of Urology Published:2019


Abstract

Purpose:Bladder cancer is among the leading causes of cancer death worldwide. Data on the bladder cancer burden are valuable for policy-making. We aimed to estimate the burden of bladder cancer by country, age group, gender and sociodemographic status between 1990 and 2016.Materials and Methods:Data from vital registration systems and cancer registries were the input to estimate the bladder cancer burden. Mortality was estimated in an ensemble model approach, incidence was estimated by dividing mortality by the mortality-to-incidence ratio and prevalence was estimated using the mortality-to-incidence ratio as a surrogate for survival. We modeled the years lived with disability using disability weights of bladder cancer sequelae. Years of life lost were calculated by multiplying the number of deaths by age by the standard life expectancy at that age. Disability adjusted life-years were calculated by summing the years lived with disability and the years of life lost. Moreover, we also estimated the burden attributable to bladder cancer risk factors, smoking and high fasting plasma glucose using the comparative risk assessment framework of the Global Burden of Disease study.Results:In 2016 there were 437,442 incident cases (95% UI 426,709-447,912) of bladder cancer with an age standardized incidence rate of 6.69/100,000 (95% UI 6.52-6.85). Bladder cancer led to 186,199 deaths (95% UI 180,453-191,686) in 2016 with an age standardized rate of 2.94/100,000 (95% UI 2.85-3.03). Bladder cancer was responsible for 3,315,186 disability adjusted life-years (95% UI 3,193,248-3,425,530) in 2016 with an age standardized rate of 49.45/100,000 (95% UI 47.68-51.11). Of bladder cancer deaths 26.84% (95% UI 19.78-33.91) and 7.29% (95% UI 1.49-16.19) were due to smoking and high fasting glucose, respectively, in 2016.Conclusions:Although the number of bladder cancer incident cases is growing globally, the age standardized incidence and number of deaths are decreasing, as mirrored by a decreasing smoking contribution. © 2019 by American Urological Association Education and Research, Inc.
Experts (# of related papers)